Download PDF
Thromb Haemost 2000; 83(06): 840-843
DOI: 10.1055/s-0037-1613930
Commentary
Schattauer GmbH

Prothrombotic Risk Factors in Children with Acute Lymphoblastic Leukemia Treated with Delayed E. coli Asparaginase (COALL-92 and 97 Protocols)

Christine Mauz-Körholz
1   From the Department of Paediatric Haematology and Oncology, Heinrich-Heine University Medical Centre Düsseldorf
,
Ralf Junker
3   Department of Clinical Chemistry and Laboratory Medicine/Institute of Arteriosclerosis Research, Westfälische-Wilhelms-University Medical Centre, Münster, Germany
,
Ulrich Göbel
1   From the Department of Paediatric Haematology and Oncology, Heinrich-Heine University Medical Centre Düsseldorf
,
Ulrike Nowak-Göttl
2   Department of Paediatric Haematology and Oncology
› Author Affiliations
Further Information

Publication History

Received 01 October 1999

Accepted after resubmission 20 January 2000

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

Summary

Hereditary prothrombotic risk factors have been shown to increase the risk of venous thrombosis in children treated with the combination of E. coli asparaginase and steroids. In the present study the role of prothrombotic risk factors in children with ALL treated according to the COALL study protocol was investigated in 108 consecutively recruited childhood patients. The prevalence rates of prothrombotic risk factors [factor V G1691A mutation, the prothrombin G20210A variant, the TT677 methylenetetrahydrofolate reductase genotype, deficiencies of protein C, protein S, antithrombin, elevated lipoprotein (a)] in this cohort were within the range reported for healthy Caucasians, and comparable to previously reported data for other leukemic patients. Venous thromboembolism occurred in 3 of the 108 children (induction n = 1; reinduction n = 2: 2.8%), and none of these children carried a prothrombotic risk factor. The results of the present study, suggest that the role of hereditary and acquired disturbances of coagulation in the development of thromboses might depend on the treatment regimen.

Keywords

Childhood ALL - prothrombotic risk factors - symptomatic thromboembolism
 

  • References

  • 1 Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol 1987; 05: 811-7.
    CrossrefPubMedGoogle Scholar
  • 2 Mitchell L, Hoogendoorn H, Giles AR, Vegh PA, Andrew MA. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood 1994; 83: 386-91.
    CrossrefPubMedGoogle Scholar
  • 3 Nowak-Göttl U, Wolff JEA, Kuhn N, Boos J, Kehrel B, Lilienweiss V, Schwabe D, Jürgens H. Enhanced thrombin generation, p-von Willebrand factor, p-fibrin D-dimer and p-plasminogen activator inhibitor 1: Predictive for venous thrombosis in asparaginase-treated children. Fibrinolysis 1994; 08: 63-5.
    PubMedGoogle Scholar
  • 4 Semeraro N, Montemurro P, Giordano P, Schettini F, Santoro N, De Mattia D, Giordano D, Conese M, Colucci M. Unbalanced coagulation – fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukemia. Thromb Haemost 1990; 64: 38-40.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Miniero R, Saracco P, Einaudi S, Garofalo F, Lange MM, Madon E. L-asparaginase-induced coagulopathy in children with acute lymphoblastic leukemia. Drugs Exptl Clin Res 1987; 13: 377-9.
    PubMedGoogle Scholar
  • 6 Shapiro AD, Clarke SL, Christian JM, Odom LF, Hathaway WE. Thrombosis in children receiving L-asparaginase. Determining patients at risk. Am J Pediatr Hematol Oncol 1993; 15: 400-5.
    PubMedGoogle Scholar
  • 7 Nowak-Göttl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, Schwabe D, Ehrenforth S. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93: 1595-9.
    PubMedGoogle Scholar
  • 8 Sutor AH, Mall V, Thomas KB. Bleeding and thrombosis in children with acute lymphoblastic leukemia treated according to the ALL-BFM-90 protocol. Klin Pädiatr 1992; 211: 201-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Eckhof-Donovan S, Schwamborn D, Körholz D, Michelmann Iv, Kries R, Nürnberger W, Göbel U. Thromboses in children with acute lymphoblastic leukemia treated by the COALL-protocol. Klin Pädiatr 1994; 206: 327-30.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Mauz-Körholz C, Nürnberger W, Irsfeld H, Körholz D, Göbel U. Low incidence of severe venous thromboses in 10 children with ALL treatment according to COALL-92 and -97 protocol. Klin Pädiatr 1999; 211: 215-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, Heijer den M, Kluijtman LAJ, Heuvel van den LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995; 10: 111-3.
    CrossrefPubMedGoogle Scholar
  • 12 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, Ronde de H, Velden van der PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
    CrossrefPubMedGoogle Scholar
  • 13 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
    PubMedGoogle Scholar
  • 14 Nowak-Göttl U, Junker R, Hartmeier M, Koch HG, Münchow N, Assmann G, von Eckardstein E. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100: 743-8.
    CrossrefPubMedGoogle Scholar
  • 15 Sarris AH, Kempin S, Berman E, Michaeli J, Little C, Andreeff M, Gee T, Straus D, Gansbacher B, Filippa D, Glaser B, Clarkson B. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992; 79: 1305-10.
    PubMedGoogle Scholar
  • 16 De Stefano V, Gugliotta L, Mazzucconi MG, Leone G, Mandelli F. for the GIMEMA. Hypercoagulability during induction therapy of acute lymphoblastic leukemia is of scarce clinical relevance. Blood 1992; 81: 2468-9.
    PubMedGoogle Scholar
  • 17 Solano C, Lopez J, Gomez N, Fernandez-Ranada JM. Acute lymphoblastic leukemia: Hypofibrinogenemia with a low incidence of clinical complications is often found during induction remission therapy. Blood 1992; 80: 1366-7.
    PubMedGoogle Scholar
  • 18 Leone G, Gugliotta L, Mazzucconi MG, de Stefano V, Belmonte MM, Dragoni F, Specchia G, Centra A, Gamba G, Camera A, Mandelli F. Evidence of a hypercoagulable state in patients with ALL treated with low dose of E. coli L-asparaginase – A GIMEMA study. Thromb Haemost 1993; 69: 12-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Korte W, Feldges A, Baumgartner C, Ullmann S, Niederer V, Schmid L. Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report. Klin Pädiatr 1994; 206: 331-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Kirschke R, Nürnberger W, Eckhof-Donovan S, Nürnberger I, Göbel U. Coagulation and fibrinolysis in children with acute lymphoblastic leukemia treated according to the COALL-05-92-protocol. Klin Pädiatr 1998; 210: 285-90.
    Article in Thieme ConnectPubMedGoogle Scholar